Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Disease Progression in Huntington Disease: An Analysis of Multiple Longitudinal Outcomes.

Garcia TP, Wang Y, Shoulson I, Paulsen JS, Marder K.

J Huntingtons Dis. 2018;7(4):337-344. doi: 10.3233/JHD-180297.

PMID:
30400103
2.

Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease.

Tanner C, Marder K, Eberly S, Biglan K, Oakes D, Shoulson I; Huntington Study Group Prospective Huntington At-Risk Observational Study Investigators.

Mov Disord. 2018 Mar;33(3):472-478. doi: 10.1002/mds.27239. Epub 2018 Jan 3.

PMID:
29297592
3.

A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.

Gourgari E, Wilhelm EE, Hassanzadeh H, Aroda VR, Shoulson I.

J Diabetes Complications. 2017 Dec;31(12):1719-1727. doi: 10.1016/j.jdiacomp.2017.08.005. Epub 2017 Aug 12. Review.

4.

Erratum to: Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases.

Purks JL, Wilhelm EE, Shoulson I, Creveling J, Dorsey ER, Irony T, LoCastro TM, Pagan F, Ravina B, Simuni T, Sterling M, Tariot P, Anderson KE.

Patient. 2017 Oct;10(5):667-668. doi: 10.1007/s40271-017-0271-7. No abstract available.

PMID:
28766071
5.

I-SPY 2 Breast Cancer Trial as a Model for Innovation in Alzheimer Disease Therapies.

Messmer MF, Wilhelm EE, Shoulson I.

JAMA Neurol. 2017 Sep 1;74(9):1027-1028. doi: 10.1001/jamaneurol.2017.1528. No abstract available.

PMID:
28738114
6.

Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases.

Purks JL, Wilhelm EE, Shoulson I, Creveling J, Dorsey ER, Irony T, LoCastro TM, Pagan F, Ravina B, Simuni T, Sterling M, Tariot P, Anderson KE.

Patient. 2017 Oct;10(5):541-544. doi: 10.1007/s40271-017-0257-5. No abstract available. Erratum in: Patient. 2017 Oct;10 (5):667-668.

7.

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.

Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR; HBS; CamPaIGN; PICNICS; PROPARK; PSG; DIGPD; PDBP.

Lancet Neurol. 2017 Aug;16(8):620-629. doi: 10.1016/S1474-4422(17)30122-9. Epub 2017 Jun 16. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

8.

A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease.

Hayete B, Wuest D, Laramie J, McDonagh P, Church B, Eberly S, Lang A, Marek K, Runge K, Shoulson I, Singleton A, Tanner C, Khalil I, Verma A, Ravina B.

PLoS One. 2017 Jun 12;12(6):e0178982. doi: 10.1371/journal.pone.0178982. eCollection 2017.

9.

A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).

Biglan KM, Oakes D, Lang AE, Hauser RA, Hodgeman K, Greco B, Lowell J, Rockhill R, Shoulson I, Venuto C, Young D, Simuni T; Parkinson Study Group STEADY‐PD III Investigators.

Ann Clin Transl Neurol. 2017 May 9;4(6):360-368. doi: 10.1002/acn3.412. eCollection 2017 Jun.

10.

Risk Factors for Suicidal Ideation in People at Risk for Huntington's Disease.

Anderson KE, Eberly S, Groves M, Kayson E, Marder K, Young AB, Shoulson I; PHAROS Investigators.

J Huntingtons Dis. 2016 Dec 15;5(4):389-394.

PMID:
27983561
11.

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators.

Neurology. 2017 Jan 10;88(2):152-159. doi: 10.1212/WNL.0000000000003478. Epub 2016 Dec 2.

12.

Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS).

Quaid KA, Eberly SW, Kayson-Rubin E, Oakes D, Shoulson I; Huntington Study Group PHAROS Investigators and Coordinators.

Clin Genet. 2017 Jun;91(6):824-831. doi: 10.1111/cge.12893. Epub 2016 Nov 24.

13.

HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).

Carlozzi NE, Schilling SG, Lai JS, Paulsen JS, Hahn EA, Perlmutter JS, Ross CA, Downing NR, Kratz AL, McCormack MK, Nance MA, Quaid KA, Stout JC, Gershon RC, Ready RE, Miner JA, Barton SK, Perlman SL, Rao SM, Frank S, Shoulson I, Marin H, Geschwind MD, Dayalu P, Goodnight SM, Cella D.

Qual Life Res. 2016 Oct;25(10):2441-2455. doi: 10.1007/s11136-016-1386-3. Epub 2016 Aug 13.

14.

Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease: Corrigendum.

Oster E, Shoulson I, Dorsey ER.

Am Econ Rev. 2016 Jun;106(6):1562-5.

PMID:
29547253
15.

Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease.

Kurlan R, Ravina B, Eberly S, Lang AE, Tanner CM, Marek K, Marder K, Beck J, Elliott R, Oakes D, Shoulson I; PSG PostCEPT (LABS‐PD) Investigators.

Mov Disord Clin Pract. 2015 Dec 14;3(1):53-58. doi: 10.1002/mdc3.12273. eCollection 2016 Jan-Feb.

16.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C.

JAMA Neurol. 2016 Jan;73(1):102-10. doi: 10.1001/jamaneurol.2015.2736.

PMID:
26569098
17.

Informativeness of Early Huntington Disease Signs about Gene Status.

Oster E, Eberly SW, Dorsey ER, Kayson-Rubin E, Oakes D, Shoulson I.

J Huntingtons Dis. 2015;4(3):271-7. doi: 10.3233/JHD-150156.

PMID:
26444024
18.

Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease.

Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, Selkoe DJ, Oakes D, Shoulson I, Dong X, Marek K, Zheng B, Ivinson A, Hyman BT, Growdon JH, Sudarsky LR, Schlossmacher MG, Ravina B, Scherzer CR.

Brain. 2015 Sep;138(Pt 9):2659-71. doi: 10.1093/brain/awv202. Epub 2015 Jul 28.

19.

Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study.

Ravina B, Eberly S, Oakes D, Lang AE, Dodelet V, Roos P, Harman J, Shoulson I, Schipper HM.

Biomark Med. 2015;9(2):89-97. doi: 10.2217/bmm.14.103.

PMID:
25689898
20.

Mendelian randomization of serum urate and parkinson disease progression.

Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A; Parkinson Study Group.

Ann Neurol. 2014 Dec;76(6):862-8. doi: 10.1002/ana.24281. Epub 2014 Oct 3.

21.

Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial.

Jennings D, Eberly S, Oakes D, Seibyl J, Marek K, Shoulson I; Parkinson Study Group PRECEPT Investigators.

J Parkinsons Dis. 2014;4(4):629-38. doi: 10.3233/JPD-140383.

PMID:
25062961
22.

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.

Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D; Parkinson Study Group PRECEPT Investigators.

Neurology. 2014 May 20;82(20):1791-7. doi: 10.1212/WNL.0000000000000424. Epub 2014 Apr 23.

23.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
24.

Approaches and costs for sharing clinical research data.

Wilhelm EE, Oster E, Shoulson I.

JAMA. 2014 Mar 26;311(12):1201-2. doi: 10.1001/jama.2014.850. No abstract available.

PMID:
24556937
25.

A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study.

Tanner CM, Meng CC, Ravina B, Lang A, Kurlan R, Marek K, Oakes D, Seibyl J, Flagg E, Gauger L, Guest DD, Goetz CG, Kieburtz K, DiEuliis D, Fahn S, Elliott RA, Shoulson I.

Mov Disord. 2014 May;29(6):743-9. doi: 10.1002/mds.25814. Epub 2014 Feb 11.

26.

Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.

Harris M, Bhuvaneshwar K, Natarajan T, Sheahan L, Wang D, Tadesse MG, Shoulson I, Filice R, Steadman K, Pishvaian MJ, Madhavan S, Deeken J.

Pharmacogenet Genomics. 2014 Feb;24(2):81-93. doi: 10.1097/FPC.0000000000000015. Erratum in: Pharmacogenet Genomics. 2014 Jun;24(6):329.

27.

Data sharing for public health research: A qualitative study of industry and academia.

Saunders PA, Wilhelm EE, Lee S, Merkhofer E, Shoulson I.

Commun Med. 2014;11(2):179-87.

PMID:
26596125
28.

Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K.

JAMA Neurol. 2014 Feb;71(2):141-50. doi: 10.1001/jamaneurol.2013.5528.

29.

Natural history of Huntington disease.

Dorsey ER, Beck CA, Darwin K, Nichols P, Brocht AF, Biglan KM, Shoulson I; Huntington Study Group COHORT Investigators.

JAMA Neurol. 2013 Dec;70(12):1520-30. doi: 10.1001/jamaneurol.2013.4408.

PMID:
24126537
30.

Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments.

Lang AE, Eberly S, Goetz CG, Stebbins G, Oakes D, Marek K, Ravina B, Tanner CM, Shoulson I; LABS-PD investigators.

Mov Disord. 2013 Dec;28(14):1980-6. doi: 10.1002/mds.25671. Epub 2013 Oct 9.

PMID:
24123383
31.

Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.

Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson I; Huntington Study Group PHAROS Investigators.

JAMA Neurol. 2013 Nov;70(11):1382-8. doi: 10.1001/jamaneurol.2013.3487.

32.

HTRF analysis of soluble huntingtin in PHAROS PBMCs.

Moscovitch-Lopatin M, Goodman RE, Eberly S, Ritch JJ, Rosas HD, Matson S, Matson W, Oakes D, Young AB, Shoulson I, Hersch SM; Huntington Study Group PHAROS Investigators.

Neurology. 2013 Sep 24;81(13):1134-40. doi: 10.1212/WNL.0b013e3182a55ede. Epub 2013 Aug 21.

33.

Limited Life Expectancy, Human Capital and Health Investments.

Oster E, Shoulson I, Dorsey ER.

Am Econ Rev. 2013 Aug;103(5):1977-2002. No abstract available.

PMID:
29533058
34.

In Memoriam: Robert J. Joynt, MD, PhD (1925-2012).

Shoulson I.

Arch Neurol. 2012 Nov 1;69(11):1518-9. doi: 10.1001/archneurol.2012.2265. No abstract available.

PMID:
23753728
35.

Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.

Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, Shoulson I.

Neurology. 2013 May 28;80(22):2022-7. doi: 10.1212/WNL.0b013e318294b304. Epub 2013 Apr 26.

36.

Reply: Unusual DAT scan results.

Ravina B, Marek K, Eberly S, Oakes D, Shoulson I.

Mov Disord. 2013 Jun;28(6):847. doi: 10.1002/mds.25447. Epub 2013 Apr 4. No abstract available.

PMID:
23559090
37.

Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study.

Dorsey ER, Brocht AF, Nichols PE, Darwin KC, Anderson KE, Beck CA, Singh S, Biglan KM, Shoulson I.

J Huntingtons Dis. 2013;2(4):509-15. doi: 10.3233/JHD-130071.

PMID:
25062735
38.

Knowledge of the Genetic Information Nondiscrimination act among individuals affected by Huntington disease.

Dorsey ER, Darwin KC, Nichols PE, Kwok JH, Bennet C, Rosenthal LS, Bombard Y, Shoulson I, Oster E.

Clin Genet. 2013 Sep;84(3):251-7. doi: 10.1111/cge.12065. Epub 2012 Dec 20.

PMID:
23167775
39.

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.

Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I.

Mov Disord. 2012 Sep 15;27(11):1392-7. doi: 10.1002/mds.25157. Epub 2012 Sep 13.

40.

TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease.

Lee JH, Lee JM, Ramos EM, Gillis T, Mysore JS, Kishikawa S, Hadzi T, Hendricks AE, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Gellera C, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Landwehrmeyer GB; Registry Study of the European Huntington's Disease Network, Shoulson I; Huntington Study Group COHORT project, Myers RH, MacDonald ME, Gusella JF.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):404-8. Epub 2012 Jul 3.

41.

Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10.

Biglan KM, Dorsey ER, Evans RV, Ross CA, Hersch S, Shoulson I, Matson W, Kieburtz K; Huntington Study Group Pre-2CARE Investigators.

J Huntingtons Dis. 2012;1(1):65-9. doi: 10.3233/JHD-2012-120007.

42.

Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study.

Dorsey R, Biglan K, Eberly S, Auinger P, Brocht A, Umeh CC, Oakes D, Clarence-Smith K, Marshall F, Shoulson I, Frank S.

PLoS Curr. 2011 Nov 13;3:RRN1283. doi: 10.1371/currents.RRN1283.

43.

Milestones in huntington disease.

Shoulson I, Young AB.

Mov Disord. 2011 May;26(6):1127-33. doi: 10.1002/mds.23685. Review.

PMID:
21626556
44.

Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".

Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A; Parkinson Study Group PRECEPT Investigators.

Mov Disord. 2011 Aug 15;26(10):1864-8. doi: 10.1002/mds.23741. Epub 2011 Apr 29.

45.

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.

Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE; Parkinson Study Group DATATOP and PRECEPT investigators.

Mov Disord. 2011 Mar;26(4):608-13. doi: 10.1002/mds.23581. Epub 2011 Feb 1.

PMID:
21287602
46.

Altered cholesterol and fatty acid metabolism in Huntington disease.

Block RC, Dorsey ER, Beck CA, Brenna JT, Shoulson I.

J Clin Lipidol. 2010 Jan-Feb;4(1):17-23. doi: 10.1016/j.jacl.2009.11.003. Review.

47.

Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.

Huntington Study Group Pre2CARE Investigators, Hyson HC, Kieburtz K, Shoulson I, McDermott M, Ravina B, de Blieck EA, Cudkowicz ME, Ferrante RJ, Como P, Frank S, Zimmerman C, Cudkowicz ME, Ferrante K, Newhall K, Jennings D, Kelsey T, Walker F, Hunt V, Daigneault S, Goldstein M, Weber J, Watts A, Beal MF, Browne SE, Metakis LJ.

Mov Disord. 2010 Sep 15;25(12):1924-8. doi: 10.1002/mds.22408.

PMID:
20669312
48.

Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.

Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C.

Mov Disord. 2010 Sep 15;25(12):1801-8. doi: 10.1002/mds.23006.

PMID:
20669311
49.

In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study.

Williams JK, Erwin C, Juhl AR, Mengeling M, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS; I-RESPOND-HD Investigators of the Huntington Study Group.

Am J Med Genet B Neuropsychiatr Genet. 2010 Sep;153B(6):1150-9. doi: 10.1002/ajmg.b.31080.

50.

Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study.

Erwin C, Williams JK, Juhl AR, Mengeling M, Mills JA, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS; I-RESPOND-HD Investigators of the Huntington Study Group.

Am J Med Genet B Neuropsychiatr Genet. 2010 Jul;153B(5):1081-93. doi: 10.1002/ajmg.b.31079.

Supplemental Content

Loading ...
Support Center